webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide

  CAS No.: 1226305-62-9   Cat No.: BADC-00558 4.5  

N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker that allows selective conjugation to antibody residues, enhancing antibody-drug conjugate targeting and payload stability.

N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide

Structure of 1226305-62-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C18H19NO3
Molecular Weight
297.35
Shipping
Room temperature, or blue ice upon request.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
N-[2-(3,5-dimethylphenoxy)ethyl]-4-formylbenzamide
Canonical SMILES
CC1=CC(=CC(=C1)OCCNC(=O)C2=CC=C(C=C2)C=O)C
InChI
InChI=1S/C18H19NO3/c1-13-9-14(2)11-17(10-13)22-8-7-19-18(21)16-5-3-15(12-20)4-6-16/h3-6,9-12H,7-8H2,1-2H3,(H,19,21)
InChIKey
AUBXJQHNGVLGJJ-UHFFFAOYSA-N
Shipping
Room temperature, or blue ice upon request.

N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is an emerging compound in the field of medicinal chemistry, recognized for its unique structural attributes and potential therapeutic applications. By featuring both dimethylphenoxy and formylbenzamide groups, this compound is well-positioned to engage in various biochemical interactions which may be critical for its efficacy in diverse medical applications. The exploration of such compounds is crucial as researchers strive to discover new drugs that can tackle complex diseases with improved safety and efficacy profiles. As such, N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide represents a promising candidate in the pipeline of potential pharmacological innovations.

One of the foremost applications of N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is its potential role in cancer therapy. The compound is being studied for its ability to selectively inhibit tumor growth by interfering with specific cellular pathways involved in cancer cell proliferation and survival. This characteristic makes it an attractive candidate for targeted cancer therapy, potentially reducing the side effects often associated with conventional chemotherapy. By contributing to the apoptosis of malignant cells while sparing normal, healthy cells, this compound could represent a significant advancement in the treatment of various cancers, including those resistant to existing therapeutic approaches.

Beyond oncology, N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is also being investigated for possible applications in anti-inflammatory treatment. Its chemical structure suggests potential efficacy in modulating inflammatory responses, which could be beneficial in managing chronic inflammatory conditions such as rheumatoid arthritis and asthma. By dampening excessive inflammatory signals, the compound may provide relief from symptoms and help in the maintenance of normal tissue function. Ongoing research efforts aim to validate these effects through rigorous clinical trials, with the hope of developing it into a mainstream therapeutic option for inflammatory diseases.

Additionally, N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide holds promise as a neuroprotective agent, potentially offering therapeutic value in neurological disorders. In conditions like multiple sclerosis and neurodegenerative diseases, protecting neurons from damage is critical. The compound's ability to interact with pathways that mediate neuronal survival and repair gives it potential utility in protecting or restoring nerve function. Researchers are focused on elucidating the mechanisms by which this compound can exert its neuroprotective effects, aiming to pave the way for new treatments that can improve patient outcomes in neurodegenerative and neuroinflammatory diseases. This focus underscores the compound’s versatility and its potential to address several pressing medical challenges.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 4-Formyl-N-(2-(p-Tolyloxy)ethyl)benzamide | Mal-amide-PEG3-CH2 NHS ester
Send Inquiry
Verification code
Inquiry Basket